Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.92) by 3.26 percent. The company reported quarterly sales of $13.008 million which beat the analyst consensus estimate of $12.071 million by 7.77 percent. This is a 2.64 percent increase over sales of $12.674 million the same period last year.
Sutro Biopharma Q1 2024 Adj EPS $(0.95) Misses $(0.92) Estimate, Sales $13.008M Beat $12.071M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.